TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder: Predictors of Change
Brief Summary: This study will compare the effectiveness of two treatments, dialectical behavior therapy versus fluoxetine with clinical management, for reducing the risk of self-injury and suicidal behavior in people with borderline personality disorder.


Options:
A: Arm Label: Fluoxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluoxetine, Drug: Citalopram | Arm Label: Dialectical behavior therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DBT | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Fluoxetine | Intervention Type: BEHAVIORAL; Name: DBT; Assigned to Arm(s): Dialectical behavior therapy | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): Fluoxetine
B: Arm Label: Psychosocial group intervention; Type: EXPERIMENTAL; Interventions: Behavioral: 10 weekly group meetings, Behavioral: Outpatient counseling and support groups | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Outpatient counseling and support groups | Intervention Type: BEHAVIORAL; Name: 10 weekly group meetings; Assigned to Arm(s): Psychosocial group intervention | Intervention Type: BEHAVIORAL; Name: Outpatient counseling and support groups; Assigned to Arm(s): Control, Psychosocial group intervention
C: Arm Label: Decision Aid Group; Type: EXPERIMENTAL; Interventions: Behavioral: Decision Aid | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Decision Aid; Assigned to Arm(s): Decision Aid Group
D: Arm Label: Telephone-based management; Type: EXPERIMENTAL; Interventions: Behavioral: Treatment as Usual | Arm Label: iFightDepression for Suicide; Type: EXPERIMENTAL; Interventions: Behavioral: Treatment as Usual | Arm Label: Treatment as Usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Telephone-based management, Behavioral: iFightDepression for Suicide | Arm Label: Self Awareness of Mental Health; Type: EXPERIMENTAL; Interventions: Behavioral: Treatment as Usual, Behavioral: Self Awareness of Mental Health | Intervention Type: BEHAVIORAL; Name: Telephone-based management; Assigned to Arm(s): Treatment as Usual | Intervention Type: BEHAVIORAL; Name: iFightDepression for Suicide; Assigned to Arm(s): Treatment as Usual | Intervention Type: BEHAVIORAL; Name: Treatment as Usual; Assigned to Arm(s): Self Awareness of Mental Health, Telephone-based management, iFightDepression for Suicide | Intervention Type: BEHAVIORAL; Name: Self Awareness of Mental Health; Assigned to Arm(s): Self Awareness of Mental Health

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Treating Suicidal Behavior and Self-Mutilation in Borderline Personality Disorder: Predictors of Change
Brief Summary: This study will compare the effectiveness of two treatments, dialectical behavior therapy versus fluoxetine with clinical management, for reducing the risk of self-injury and suicidal behavior in people with borderline personality disorder.


Options:
A: Arm Label: Youth-Nominated Support Team; Type: EXPERIMENTAL; Interventions: Behavioral: Youth-Nominated Support Team | Arm Label: Enhanced Treatment as Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Youth-Nominated Support Team; Assigned to Arm(s): Youth-Nominated Support Team
B: Arm Label: ASSIP plus SPP; Type: EXPERIMENTAL; Interventions: Behavioral: Attempted Suicide Short Intervention Program (ASSIP), Behavioral: Suicide Prevention Pathway (SPP) | Arm Label: CBT plus SPP; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioural Therapy (CBT), Behavioral: Suicide Prevention Pathway (SPP) | Arm Label: SPP alone; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Suicide Prevention Pathway (SPP) | Intervention Type: BEHAVIORAL; Name: Attempted Suicide Short Intervention Program (ASSIP); Assigned to Arm(s): ASSIP plus SPP | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioural Therapy (CBT); Assigned to Arm(s): CBT plus SPP | Intervention Type: BEHAVIORAL; Name: Suicide Prevention Pathway (SPP); Assigned to Arm(s): ASSIP plus SPP, CBT plus SPP, SPP alone
C: Arm Label: Fluoxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluoxetine, Drug: Citalopram | Arm Label: Dialectical behavior therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: DBT | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): Fluoxetine | Intervention Type: BEHAVIORAL; Name: DBT; Assigned to Arm(s): Dialectical behavior therapy | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): Fluoxetine
D: Arm Label: TFP; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Transference-Focused Psychotherapy | Arm Label: ECP; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: treatment by experienced community psychotherapists | Intervention Type: BEHAVIORAL; Name: Transference-Focused Psychotherapy; Assigned to Arm(s): TFP | Intervention Type: BEHAVIORAL; Name: treatment by experienced community psychotherapists; Assigned to Arm(s): ECP

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I/II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety of Eptifibatide as Treatment for Acute Pain Episodes in Sickle Cell Disease
Brief Summary: This study will evaluate the safety of eptifibatide in sickle cell patients and how well it works during the course of painful crises. The overall hypothesis that we seek to test is that increased platelet activation and the resultant inflammatory responses are important contributors to the problems of sickle cell disease. Sickle cell disease has been referred to both as a condition associated with increased risk of blood clots and increased inflammation. A painful crisis represents the most common cli nical problem in sickle cell disease, but the treatment of these crises remains inadequate.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ibuprofen, Drug: Diamorphine or Morphine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Diamorphine or Morphine | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Diamorphine or Morphine; Assigned to Arm(s): 1, 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Eptifibatide | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Eptifibatide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: GMI-1070; Type: EXPERIMENTAL; Interventions: Drug: GMI-1070 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: GMI-1070; Assigned to Arm(s): GMI-1070 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: High Demand / Low Infusion; Type: OTHER; Interventions: Other: High Demand / Low Infusion | Arm Label: Low Demand / High Infusion; Type: OTHER; Interventions: Other: PCA Dosing Plan | Intervention Type: OTHER; Name: High Demand / Low Infusion; Assigned to Arm(s): High Demand / Low Infusion | Intervention Type: OTHER; Name: PCA Dosing Plan; Assigned to Arm(s): Low Demand / High Infusion

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective Randomized Clinical Trial Comparing Laparoscopic Cholecystectomy and Hybrid Natural Orifice Translumenal Endoscopic Surgery (NOTES)
Brief Summary: The purpose of the study is to determine the feasibility of cholecystectomy made by a transvaginal approach with a NOTES procedure (natural orifice translumenal endoscopic surgery).


Options:
A: Arm Label: LESS cholecystectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Cholecystectomy | Arm Label: Standard LAP-CHOLE; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Cholecystectomy | Arm Label: LESS Cholecystectomy not blind; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Cholecystectomy | Intervention Type: PROCEDURE; Name: Cholecystectomy; Assigned to Arm(s): LESS Cholecystectomy not blind, LESS cholecystectomy, Standard LAP-CHOLE
B: Arm Label: Laparoscopy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Cholecystectomy | Arm Label: Transumbilical; Type: EXPERIMENTAL; Interventions: Procedure: Cholecystectomy | Arm Label: Transvaginal; Type: EXPERIMENTAL; Interventions: Procedure: Transvaginal hybrid NOTES cholecystectomy, Procedure: Cholecystectomy | Intervention Type: PROCEDURE; Name: Transvaginal hybrid NOTES cholecystectomy; Assigned to Arm(s): Transvaginal | Intervention Type: PROCEDURE; Name: Cholecystectomy; Assigned to Arm(s): Laparoscopy, Transumbilical, Transvaginal
C: Arm Label: Multi port; Type: ACTIVE_COMPARATOR; Interventions: Procedure: 4-Ports Cholecystectomy (4PC) | Arm Label: Single port; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Single-Port Cholecystectomy (SPC) | Intervention Type: PROCEDURE; Name: 4-Ports Cholecystectomy (4PC); Assigned to Arm(s): Multi port | Intervention Type: PROCEDURE; Name: Single-Port Cholecystectomy (SPC); Assigned to Arm(s): Single port
D: Arm Label: Single port laparoscopic device; Type: EXPERIMENTAL; Interventions: Device: Single port laparoscopic cholecystectomy SINGLE SITE LAPAROSCOPY ACCESS SYSTEM (Johnson & Johnson Medical Spa) | Arm Label: Four-port laparoscopic device; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Four port laparoscopic cholecystectomy surgery | Intervention Type: DEVICE; Name: Single port laparoscopic cholecystectomy SINGLE SITE LAPAROSCOPY ACCESS SYSTEM (Johnson & Johnson Medical Spa); Assigned to Arm(s): Single port laparoscopic device | Intervention Type: PROCEDURE; Name: Four port laparoscopic cholecystectomy surgery; Assigned to Arm(s): Four-port laparoscopic device

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Osteosynthesis, Primary Hemi-arthroplasty, and Non-surgical Management for Displaced Four-part Fractures of the Proximal Humerus in Elderly: a Multi-centre, Randomised Clinical Trial
Brief Summary: Displaced four-part fractures are among the most severe injuries of the proximal humerus. The optimal treatment is disputed and published data are inadequate for evidence-based decision making.

The investigators aim to: 1) compare the effect of angle-stable plate osteosynthesis and non-surgical management, 2) compare the effect of primary hemiarthroplasty with both osteosynthesis and non-surgical management, 3) study prognostic differences between 'valgus impacted' and 'classical' four-part fracture patterns.

The investigators will conduct a randomised, multi-centre, clinical trial including patients from ten national shoulder units within a two year period. Patients will be randomised to non-surgical treatment, hemiarthroplasty or angle-stable plate osteosynthesis. All patients will receive a standardised three-month rehabilitation program of supervised physiotherapy. Patients will be followed at least one year and will be assessed blindly according to a standardised evaluation protocol including Constant Disability Scale, Oxford Shoulder Score, and Short Form-36.


Options:
A: Arm Label: Intervention Armeo®Spring; Type: ACTIVE_COMPARATOR; Interventions: Other: Intervention Armeo®Spring | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: Control Group | Intervention Type: OTHER; Name: Intervention Armeo®Spring; Assigned to Arm(s): Intervention Armeo®Spring | Intervention Type: OTHER; Name: Control Group; Assigned to Arm(s): Control group
B: Arm Label: Osteosynthesis; Type: EXPERIMENTAL; Interventions: Procedure: Osteosynthesis | Arm Label: Non-surgical; Type: EXPERIMENTAL; Interventions: Procedure: Non-surgical management | Arm Label: Hemiarthroplasty; Type: EXPERIMENTAL; Interventions: Procedure: Hemiarthroplasty | Intervention Type: PROCEDURE; Name: Non-surgical management; Assigned to Arm(s): Non-surgical | Intervention Type: PROCEDURE; Name: Osteosynthesis; Assigned to Arm(s): Osteosynthesis | Intervention Type: PROCEDURE; Name: Hemiarthroplasty; Assigned to Arm(s): Hemiarthroplasty
C: Arm Label: Conservative /Physiotherapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Surgery with LCP T plate; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgical treatment with LCP | Intervention Type: PROCEDURE; Name: Surgical treatment with LCP; Assigned to Arm(s): Surgery with LCP T plate
D: Arm Label: Telerehabilitation; Type: EXPERIMENTAL; Interventions: Other: Rehabilitation (Physiotherapy) | Arm Label: Face-to-face intervention in a clinic; Type: ACTIVE_COMPARATOR; Interventions: Other: Rehabilitation (Physiotherapy) | Intervention Type: OTHER; Name: Rehabilitation (Physiotherapy); Assigned to Arm(s): Face-to-face intervention in a clinic, Telerehabilitation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cervical Preparation Before Same-day Second Trimester Abortion With Buccal Misoprostol Versus Dilapan-S: A Randomized Placebo Controlled Trial
Brief Summary: The purpose of this study is to compare the dilatory effect of 400 mcg of buccally administered misoprostol to one Dilapan-S rod placed 3-4 hours before abortion by dilation and evacuation in women who are 12 weeks 0 days to 15 weeks 0 days gestation.


Options:
A: Arm Label: pitocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: mifepristone and oxytocin | Arm Label: misopristol; Type: ACTIVE_COMPARATOR; Interventions: Drug: mifepristone and misopristol | Intervention Type: DRUG; Name: mifepristone and misopristol; Assigned to Arm(s): misopristol | Intervention Type: DRUG; Name: mifepristone and oxytocin; Assigned to Arm(s): pitocin
B: Arm Label: Misoprostol by physician; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Misoprostol treatment by midwife | Arm Label: Misoprostol by midwife; Type: EXPERIMENTAL; Interventions: Procedure: Misoprostol treatment by midwife | Intervention Type: PROCEDURE; Name: Misoprostol treatment by midwife; Assigned to Arm(s): Misoprostol by midwife, Misoprostol by physician
C: Arm Label: PO Misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol (cytotec) | Arm Label: PV Misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol (cytotec) | Arm Label: Buccal Misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol (cytotec) | Intervention Type: DRUG; Name: Misoprostol (cytotec); Assigned to Arm(s): Buccal Misoprostol, PO Misoprostol, PV Misoprostol
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Device: Dilapan-S, vitamin B-12 | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Dilapan-S, vitamin B-12; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cervical Preparation Before Same-day Second Trimester Abortion With Buccal Misoprostol Versus Dilapan-S: A Randomized Placebo Controlled Trial
Brief Summary: The purpose of this study is to compare the dilatory effect of 400 mcg of buccally administered misoprostol to one Dilapan-S rod placed 3-4 hours before abortion by dilation and evacuation in women who are 12 weeks 0 days to 15 weeks 0 days gestation.


Options:
A: Arm Label: Single dose group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: Repeated dose group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Repeated dose group, Single dose group
B: Intervention Type: DRUG; Name: Doxycycline; Assigned to Arm(s): N/A
C: Arm Label: Misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Arm Label: Manual vacuum aspiration (MVA); Type: ACTIVE_COMPARATOR; Interventions: Procedure: surgery Manual vacuum aspiration (MVA) | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: PROCEDURE; Name: surgery Manual vacuum aspiration (MVA); Assigned to Arm(s): Manual vacuum aspiration (MVA)
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: misoprostol | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Device: Dilapan-S, vitamin B-12 | Intervention Type: DRUG; Name: misoprostol; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Dilapan-S, vitamin B-12; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects With Relapsing-Remitting Multiple Sclerosis
Brief Summary: The primary objective of this study is to evaluate the long-term safety profile of BG00012 (dimethyl fumarate). Secondary objectives of this study are to evaluate the long-term efficacy of BG00012 using clinical endpoints and disability progression, to evaluate further the long-term effects of BG00012 on multiple sclerosis (MS) brain lesions on magnetic resonance imaging (MRI) scans in participants who had MRI scans as part of Studies 109MS301 (NCT00420212) and 109MS302 (NCT00451451) and to evaluate the long-term effects of BG00012 on health economics assessments and the visual function test.


Options:
A: Arm Label: BG00012 plus placebo; Type: EXPERIMENTAL; Interventions: Drug: dimethyl fumarate, Drug: Placebo | Arm Label: BG00012; Type: EXPERIMENTAL; Interventions: Drug: dimethyl fumarate | Intervention Type: DRUG; Name: dimethyl fumarate; Assigned to Arm(s): BG00012, BG00012 plus placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BG00012 plus placebo
B: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Drug: Natalizumab | Arm Label: Group 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Group 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 2
C: Arm Label: Daclizumab High Yield Process 150 mg SC; Type: EXPERIMENTAL; Interventions: Biological: BIIB019 (Daclizumab High Yield Process), Drug: Interferon beta-1a Placebo | Arm Label: IFN β-1a 30 µg IM; Type: ACTIVE_COMPARATOR; Interventions: Biological: Interferon beta-1a, Drug: Daclizumab High Yield Process Placebo | Intervention Type: BIOLOGICAL; Name: BIIB019 (Daclizumab High Yield Process); Assigned to Arm(s): Daclizumab High Yield Process 150 mg SC | Intervention Type: DRUG; Name: Interferon beta-1a Placebo; Assigned to Arm(s): Daclizumab High Yield Process 150 mg SC | Intervention Type: BIOLOGICAL; Name: Interferon beta-1a; Assigned to Arm(s): IFN β-1a 30 µg IM | Intervention Type: DRUG; Name: Daclizumab High Yield Process Placebo; Assigned to Arm(s): IFN β-1a 30 µg IM
D: Arm Label: Laquinimod 0.3 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: laquinimod 0.3 | Arm Label: Laquinimod 0.6 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: laquinimod 0.6 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: laquinimod 0.3; Assigned to Arm(s): Laquinimod 0.3 mg | Intervention Type: DRUG; Name: laquinimod 0.6; Assigned to Arm(s): Laquinimod 0.6 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Study of Metformin vs. Insulin in Pregnant Overt Diabetics (MIPOD)
Brief Summary: Many women come into pregnancy with diabetes that is controlled with either Metformin or diet control; however, the current standard of care for the treatment of preexisting diabetes in pregnancy is insulin. Metformin is widely used in the non-pregnant population for glycemic control, and has been used in pregnancy for other indications without adverse maternal or fetal outcomes. What remains unproven is the ability of Metformin to adequately control glucose in women during pregnancy.

Our goal is to randomize 100 women who enter pregnancy with diabetes that is controlled by either diet or an oral agent and women who are found to have an abnormal glucose challenge test at less than 20 weeks to either standard treatment with weight based Regular and neutral protamine Hagedorn (NPH) insulin or Metformin. Our hypothesis is that Metformin will provide glycemic control that is equivalent to insulin in these women.


Options:
A: Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: metformin | Arm Label: insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: insulin | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: insulin; Assigned to Arm(s): insulin
B: Arm Label: Levemir; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin | Arm Label: NPH; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Levemir, NPH
C: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: Insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Insulin
D: Arm Label: Metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: Insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): Insulin

Answer: D